VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 RBC Capital Markets Global Healthcare Conference taking place May 16-17, 2023 in New York, NY.
Company Fireside Chat Presentation Details:
| Date: | Tuesday, May 16, 2023 | |
| Time: | 3:05 pm Eastern Time / 12:05 pm Pacific Time | |
| Webcast: | Register here | |
| Presenters: | Ian Mortimer, President and CEO Sherry Aulin, CFO | |
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$39.21 |
| Daily Change: | 0.38 0.98 |
| Daily Volume: | 627,415 |
| Market Cap: | US$3.020B |
August 11, 2025 June 03, 2025 May 14, 2025 May 12, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
